Skip to content
value.today

Tacitus Therapeutics Inc.

🇺🇸 West Palm Beach, Florida, USAPharmaceuticalsFounded 2019
Total raised
$5 M
1 round on record
Latest round
$5 M
Dec 2019
First round on record
Dec 2019
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tacitus Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2019$5 MNo. 1$2 to $10 million

Tacitus Therapeutics Inc.: Raise no. 1, Dec 2019

Investors in this round

2 investors had bought by the notice of Jan 10, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
$2,000
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carter Cliff · Executive Officer, Director
  • Jeffrey Kennedy · Executive Officer, Director
  • Erik Lium · Director
  • Thomas Novak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “One investor was issued securities in consideration of the granting of an exclusive license from such investor to the issuer.”

Signed by Carter Cliff, Chief Executive Officer. Newest notice filed Jan 10, 2020. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tacitus Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2020).

    SEC Form D · Jan 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Tacitus Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tacitus Therapeutics Inc.
NameRoleNamed in
Carter CliffExecutive officerJan 2020
Jeffrey KennedyExecutive officerJan 2020
Carter CliffDirectorJan 2020
Erik LiumDirectorJan 2020
Jeffrey KennedyDirectorJan 2020
Thomas NovakDirectorJan 2020